2024 - Case Study: EEG Digital Biomarkers in Neuropsychiatric Clinical Studies

Discover an informative webinar discussing digital biomarkers in neuropsychiatric trials, leveraging an artificial intelligence (AI)-driven platform for enhanced treatment outcomes. Drugs for psychiatric conditions suffer some of the lowest approval rates when compared to other major therapeutic areas. Underlying factors can include complex and poorly understood etiology, which are heterogeneous in presentation, and underlying pathophysiology. Additionally, traditional clinical studies fail to objectively assess cognitive function as part of patient eligibility criteria or stratify patients according to the presence or degree of cognitive impairment. Cognitive function assessments and electroencephalogram (EEG) enable the measurement of pharmacodynamic endpoints in early-stage, translational psychiatric studies, however many studies do not leverage these tools today.
Read more...
Designed to provide an industry-wide standard for real-world measurements of disease progression, the platform captures large amounts of real-world, clinical data repeated over time. The data is collected across multiple behavioral and physiological domains in the patient’s home using an EEG headset synced to a novel, tablet-based neuro-assessment platform. Together with machine learning (ML) analytics and the world’s largest database of annotated, longitudinal, neurofunctional data, Cumulus simplifies and improves the robustness of neuroscience clinical trials to provide the best and most cost-effective assessment of CNS treatment outcomes.
Join this webinar to learn how to leverage neuroassessment platforms to advance novel therapeutics focused on neuropsychiatric conditions.
Keywords: Clinical Research, Biomarkers, Clinical Data, Central Nervous System, CNS, AI, EEG